Letermovir Suppliers & Bulk Manufacturers
Available Forms: Tablet / Injection
Available Strengths: 240 mg, 480 mg, 100 mg/mL
Reference Brands: Prevymis (USA/EU)
Category:
Anti Viral
Letermovir is available in Tablet / Injection
and strengths such as 240 mg, 480 mg, 100 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Letermovir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Letermovir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Letermovir, marketed under the brand name Prevymis, is an antiviral medication used for the prevention and treatment of cytomegalovirus (CMV) infections. It is primarily indicated in adult patients undergoing allogeneic stem cell transplantation, where CMV infection can pose a significant risk. Letermovir works by selectively inhibiting the CMV DNA terminase complex, a key enzyme essential for viral replication, thereby preventing the virus from multiplying and spreading.
Beyond stem cell transplant patients, lettermovir shows potential benefits for other immunocompromised populations, including individuals with organ transplants or HIV infections, where CMV can lead to serious complications. The drug was initially developed by Bayer’s anti-infective division, later continued by AiCuris Anti-infective Cures AG through early clinical development, and subsequently acquired by Merck & Co. for Phase 3 trials and regulatory approval.
Available in both oral tablets and intravenous formulations, lettermovir provides flexible administration options tailored to patient needs. Its targeted mechanism and favorable safety profile make it a valuable therapy in the management of CMV infections, contributing to improved outcomes in patients with compromised immune systems and reducing the risk of CMV-related morbidity and mortality.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing